Germans hold hard line on drug prices; U.K. pricing moves to be unveiled this week;

@FiercePharma: Monday's top special report: Top 10 Drug Patent Losses 2014. Report | Follow @FiercePharma

@CarlyHFierce: ICYMI: J&J to pay $2.2B to wrap up longstanding Risperdal marketing probe. Story | Follow @CarlyHFierce

> German politicians agreed to continue reining in drug spending, with a mandatory discount of 7% fixed for the long term; previously, the discount was set to decline to 6% at year's end. Item

> U.K. officials are expected to announce long-awaited details of the new drug-pricing system set to take effect next year. News

> Spanish pharma company Grifols posted a 35% increase in 9-month net profit, aided by growth in U.S. sales. Report

> German blood plasma products company Biotest is under investigation by German prosecutors for alleged bribery in Russia. Report

> Biotech investments helped boost BlackRock's U.S. Opportunities fund to 29.4% growth over the past year. Story

Medical Device News

@FierceMedDev: Edwards' recall gets FDA's 'deadly' label as problems pile up. Story | Follow @FierceMedDev

@MarkHFierce: CardioDx set the terms for its IPO, upping the range. More | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Langer lab makes synthetic 'good cholesterol' for cardiovascular drug delivery. More from FierceDrugDelivery | Follow @MichaelGFierce

> Infraredx raises more cash to back imaging system ramp-up. Story

> Medtronic, Boston Scientific unleash patent fight at Supreme Court. More

Biotech News

@FierceBiotech: ImmunoGen scuttles lead PhII armed-antibody trial after tracking infection risk. More | Follow @FierceBiotech

@JohnCFierce: Novartis chopping 371 research jobs in global R&D reorganization. Goodbye, Horsham. Article | Follow @JohnCFierce

@DamianFierce: EW's long-running misfortunes continue with a Class I recall of a bypass device. Story | Follow @DamianFierce

> Midatech bags $16M round to back PhIIa studies on oral insulin program. More

> Analyst lays out 'doomsday scenario' for federal probe of AstraZeneca's Brilinta. Story

> Keryx jumps as kidney drug impresses in PhII, promises wider label. Article

Pharma Manufacturing News

> Merck to give pink slips to 500 West Point workers this holiday season. More

> PwC warns quality failings could slow growth of Indian biopharma. Story

> Developer pitches plan for Boston R&D and manufacturing complex. News

> Stalling biosimilars give Roche confidence to reopen Genentech plant. Report

> Novartis puts OTC unit and its troubled plant on second tier of sale priorities. Item

> FDA outlines plan to incentivize high-quality manufacturing. Article

Biotech Research News

@EmilyMFierce: Fewer NIH grants affected by sequestration than initially projected. Item | Follow @EmilyMFierce

> Survey details impact of federal cuts, sequestration on scientific research. More

> Key HIV protein structure revealed. Story

> Prana compound restores learning, memory loss in mice. Article

> Sage molecule could treat a wide range of CNS disorders. Report

> Study: Genetics drive neurocognitive decline in aging. More

And Finally... Animals are increasingly used to help patients with mental disorders from autism to PTSD. Report (sub. req.)

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.